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highly positive result for IgE at I week had a tracheal steno-
sis from pulmonary artery sling syndrome and had prevIOus-
ly been operated on in another institution, without document-
ed use of fibrin tissue adhesive. The preoperative serum
sample yielded negatIve results for both IgG and IgE.
Because full immunocompetence matures only within the
first years after bIrth. age seems to be a more important and
physiologic factor. This mfluence, however. was not :,ignifi-
cant in our study because the number of patients was too
small.
As far as clmical relevance of a positive antibody status is
concerned. our observation of rapidly di:,appearing IgE levels
fIts perfectly with observatIOns m mo:,t case reports III which
anaphylactic reactions to intravenous reexpo:,ure to aprotinin
occurred within a few months after primary exposure. Taking
into account the similarities of the immune responses to local
and intravenous aprotinin. we conclude that the risk of aller-
gy i:, highest in the early postoperatl\'e penod. extendlllg for
:,neral weeks. We are aware of ..( anaphylactic reaclion:,
caused by the aprotmlll component of fibrin tis:-.ue adhesive:,;
3 cases have been pubhshed3-5 and another (unpubhshed
data) occurred in a neurosurgical patient reexposed within a
few weeks. Three of these patients had IgE demonstrated: the
fourth had positive results of histamine release and lympho-
cyte transformation tests. Fortunately, all patients responded
to standard antiallergic treatment.
We agree with Schlag and SeIfert that a precise medical
history obtallled before the operation is crucial to milllmize
the risk of allergic reaction. Unfortunately. known allergies of
any type are not prognostically helpfuL as our recent study of
150 adult patients revealed: the incidence of aprotillln-specif-
ic IgG was the same among patients with and without histo-
ry of allergy.6 Yet our mo:,t recent study examilllng preopera-
tive serum samples from 520 cardiac surgical patients
indicates that a history of previous operations in di:,ciplines
with frequent use of intravenous aprotinin or tissue sealants
(eg, cardiovascular surgery and otorhinolaryngology) per-
formed not long before the mdex exposure may have a pre-
dictive power for antiaprotinin seropositivity.7
We conclude that allergic reaction, to the aprotinin compo-
nent of commercially aVailable fibrin tissue adhesives are
extremely rare. but for patients with recent aprotinin contact
III any form this risk is clilllcally relevant and has to be taken
into account before reexpo<;ure.
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Surgical implications of platelet glycoprotein IIb-
lIla inhibition
To the Editor:
We read with interest the brief communication by Alvarez l
regarding his experience with 3 patients undergoing emer-
gency coronary artery bypass grafting after platelet glycopro-
tein (Gp) Ilb-IlIa inhihition. We aIso have observed excessive
mediastmal bleedmg and increa:,ed transfw,ion requirement~
when operating on patients exposed to the GpIIb-IlIa
inhibitor abcixlmab.c Although the use of these potent
mhibltors of platelet aggregation is a major breakthrough m
the treatment of acute coronary syndromes. it is becommg
clear that operating on patient:, with actIve GplIb-IlIa mhibl-
lion represent~ a major challenge for the surgeon and a ~lg­
mticant risk. for the patient.
In our smalL retrospective series. we noted that the interval
from cessation of abciximab administration to operation was
critical m determming the degree of coagulopathy after the
operation. Patients who underwent an emergency operation
within 12 hours of admmistration had :,igniticantly greater
transfusion requirements and bleeding than did patients for
whom the operatIOn could be delayed longer than 12 hours.
ThIS clmical observation correlates WIth pharmacodynamic
studie:, of abciximab. which demon,trate a half-life of
approximately 12 hours. Platelet aggregation tS severely dys-
functIOnal in patients operated on withm thIS penod.
Optimal management of patient, undergoing emergency
cardiac operations after GpIlb-IlIa inhIbition is evolving. We
believe that there are 3 critical components for the surgical
management of these patients: (I) transfusion therapy. (2)
reduced heparinizatIOn. and (3) delay of surgical interventIon
when possible until after clearance of the inhtbitor.
Transfusion therapy with pooled platelets IS essentIal to
mcrease the number of functional platelets. Abci",imab i" ..J
chlmenc human-munne monoclonal antibody fragment that
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tightly binds the GpUb-IIIa receptor, so the pool of circulat-
ing, unbound drug is negligible. Transfused platelet~ there-
fore remain functional. The timing of platelet admIni~tratlOn
IS as yet unclear: we transfuse after weaning from cardIOpul-
monary bypa~s. Additionally, because abciximab increases
the activated clotting time in patients receiving heparin, we
recommend a reduced heparin dosage for patlent~ undergoing
cardiopulmonary bypass, with the caveat that optimal hepann
dosage in the presence of GpUb-IIIa inhibitors is as yet unde-
fined. We currently use a l50-flg/kg heparin dose and target
an activated clotting time of 500 seconds. It is also critical
that surgeons recognize the importance of delay between
administration of the particular GplIb-lIIa inhibitor and the
operation; if po~sible. waiting for a period eqUivalent to the
effective circulating half-life of the drug should be consid-
ered. Thi~ factor takes on additional relevance as newer,
shorter-actIng GpUb-IIIa reach the market (tlroflban and epti-
fibitide have recently been approved by the Food and Drug
Administration). The use of various "off-pump" techniques to
avoid cardiopulmonary bypass and full heparinization ~hould
be con~ldered when anatomically feasible and appropriate.
Finally. delay of the operation until after clearance of the
GpIIb-lIIa inhibitor i~ a reasonable strategy.
Alvarez I recommends the u~e of aprotinin as an adjunct to
hemostasi~ in patlent~ requiring an emergency operation in
the face of GpJIb-lIIa inhibition. Aprotinin reduces mediasti-
nal bleedIng In patients at high risk; however, Its salutory
effect on platelet function is mediated through the GpIb
receptor, affecting platelet adheSIOn rather than aggregation.
Although it is tempting to try anything when faced with thi~
difficult clinical problem. further information regarding the
interaction between aprotinin and GpIIb-IIIa inhibitors is cer-
tainly needed.
The importance of the platelet thrombus in acute coronary
ischemic syndromes and the ability to affect this process ha~
been called a "new frontier in myocardial reperfusion thera-
py:'3 For the significant number~ of patients who face cardiac
surgery after profound platelet inhibition. howcver, these
Inhibitors of platelet aggregation are a 2-edged sword. In hght
of the number of percutaneou~interventions performed annu-
ally in the United State~ and the number of vanous GpUb-I1Ia
Inhibitors (oral and intravenou~) coming to market, the mag-
nitude of tht~ problem I~ certain to nse. To treat patient~ In
these difficult ca~e~. cardiac ~urgeon~ will need an effective
management ,trategy that i, ba,ed on an under~tanding of the
pharmacodynamic, of the different platelet inhibitor~ and the
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Heart reduction surgery can reconstitute the residual
stress-strain state of the left ventricle
To the Editor:
Left ventricular (LV) reductIOn IS a new ~urgical therapeu-
tiC option that ha~ been devised and advanced by Bati~ta and
hi~ associate~ I for the treatment of end-stage dilated car-
diomyopathy. Resection of a large portion of the free wall of
the LV muscle mass re~ults in Significant reduction in the LV
cavity ~Ize and may improve ejection fraction. The ultimate
goal of the procedure I~ to reduce the diameter of the left ven-
tricle to restore a "more optimal" physiologiC volume/ma.,~
relationship. L' Regrettably, the ~cientific foundation for thl~
operation I~ deVOid of laboratory data. Only recently ha, there
been an attempt to formulate a physiologiC ratIOnale for thi,
operation2 using a multiple-compartment elastance model to
~Imulate the global effect~ of volume reduction on cardiac
pump mechamc,. The observed clinical benefits (improved
ejection fraction. enhanced ela~tance) of ventricular mass
reduction were based on sound theoretic argument. 2 What
remain~ i., ho\\ to explain the apparent increase in ventncular
performance that results from vanable removal of the
myocardium.
Many of the mechamsms of action attributed to volume
reduction are rooted in long-standIng belief that empha~lzes
wall stress a, the offending cause and the target variable to be
surgically manipulated. J..1 However. equating normalization
in chamber ,ize with reductIOn in wall stress may he expedi-
ent but not nece~,arily the pnnclpal mode by which thi, pro-
cedure re~tore~ myocardial functIOn. I 1
On closer examInallon, the argued chum of reduction in
active wall ~tre" is unfounded on both theoretic ground~ and
clinical findlugs. a, demomtrated by a uear doubling In cnd-
~y~tohc ela~tance after the volume reduction procedure. It is
hard If not impo"ible to reconcile the enhanced contractile
function With ,igniticant attenuation of acti\ e v. all ,tre'>'>. An
equally compelling alternati\e argument for the ob~ef\ed
nnprmement In contractile function and cardiac eneruetlc
etfIciency can be formulated. Thl' argument I, centered ,:bout
the concept ot re,ldual \\;all ,tre~,-<.,[raIn ,tate of the
myocardIUm.
A fundamental property of the heart i, it~ ability to engage
all regions and transmural layer, of myocyte,> in a collective
and nearly Uniform pattern of contractIOn. A common basic
property of many ~olid and hollow organs IS persistence of
residual strain (and hence strcss) when all external loads
(cavity pres,ure) are removed. In elastic structures such as
blood vessels and heart chambers, thi> property can be read-
